Biognosys Research Challenge

Winners of the Biognosys Research Challenge 2016

It is our great pleasure to announce the winners of the Biognosys Research Challenge 2016, a competition for one of four proteome profiling studies. The challenge was seeking to discover the most innovative research projects that benefit from Biognosys’ next-generation proteomics technology - Hyper Reaction Monitoring (HRM). HRM enables reproducible and accurate quantification of several thousand proteins in a single sample and has been successfully applied in life sciences, biotech, agriculture and other similar fields.

We would like to thank all of the participants for sending excellent applications which made it very difficult for us to select the winners. We would especially like to thank our external scientific committee for their great work: 

  • Paola Picotti, ETH Zurich, Switzerland
  • Alessandro Ori, Leibniz Institute on Aging (FLI), Germany
  • Johan Malmström, Lund University, Sweden
  • Jacob Jaffe, Broad Institute of MIT and Harvard, USA
  • Marko Jovanovic, Max Planck Institute for Brain Research, Germany
  • Markus Ralser, University of Cambridge, UK


The winners are:

Projects with tissue, cell lines or other samples


Christine Vogel, New York University

“Our research investigates protein expression during the response to environmental stress -- both at the systems level and in a highly targeted fashion. To do so, we use mass spectrometry to quantify protein concentrations, interactions, and modifications, and integrate these data with transcriptomic and translatomic information. I am excited to venture into a new era of proteomics work, in an exciting project analyzing protein changes during memory formation, as this will add another dimension to our analysis of regulatory principles that govern the cell.”


Emmanuel Varesio and Norbert Lange, University of Geneva

“Administration of 5-aminolevulinic acid (5-ALA) or its more lipophilic hexyl ester derivative (HAL) results in the temporary accumulation of phototoxic protoporphyrin IX; it is one of the most selective treatments of neoplastic tissue by photodynamic therapy (PDT). Although frequently used in clinical practice, this selectivity remains unclear and is subject to active debate. Therefore a quantitative proteomic study will help gaining deeper knowledge related to alterations occurring in heme biosynthesis while incubating cancer cells with 5-ALA. We are thankful to Biognosys to support this preliminary work and hope it will pave the way to identify potential new targets for anti-cancer agents in a broader systems biology study.”

Projects with blood or urine samples


Nicole Kruh-Garcia, Colorado State University

“Mtb has the unique ability to survive within the host macrophage; in response to the challenges of the intracellular host environment, the bacteria secretes a dynamic subset of proteins reflective of its metabolic state, that are entrapped in exosomes and released from the host cell. We have identified a panel of mycobacterial peptides in the serum exosomes of patients suspected to have TB, but who have failed to be diagnosed by smear microscopy or culture—the current gold-standards. The application of Biognosys’ Hyper Reaction Monitoring to our samples, will allow us to decipher a host protein profile in this unique sample set that is common with exosomes from individuals who have MRM confirmed TB and distinct from those of whom do not.”


Yaarub Musa, Max Planck Institute for Immunobiology and Epigenetics, and Marcin Wlodarski, University Medical Center Freiburg

“Diamond Blackfan Anemia (DBA) is a congenital bone marrow failure syndrome associated with early onset anemia that is caused by haploinsufficiency mutations in a couple of genes encoding ribosomal proteins. Consequently, the disorder leads to defects in the biogenesis of ribosomes and ultimately protein production. We would like to employ a DIA-HRM plasma proteomics approach, which is developed by Biognosys, to investigate and characterize DBA disease patients. The main aim of our study is the identification of disease biomarkers associated with this fatal disease allowing for fast and efficient diagnosis of DBA. We anticipate that this approach will help us to develop an alternative, fast, and efficient method for the prognosis and diagnosis of DBA disease.”

Winners of the past Biognosys Research Challenges


  • Elisa Noll and Wiebke Nadler, German Cancer Research Center and Heidelberg Institute for Stem Cell Technology
  • David Gomez Varela, Max Planck Institute of Experimental Medicine
  • Paul Kaschutnig, German Cancer Research Center

Biognosys Research Challenge

Biognosys was founded in 2008 as a spin-off from one of the leading European universities and highly values the importance of high-quality academic research. The Biognosys Research Challenge was started to support the academic community with generating excellent science. With positive experiences from previous years Biognosys is committed to continue with this initiative also in the future.

For more information about the Biognosys Research Challenge, please contact us at


Let us help you do great proteomics!

Please click here to contact us.